The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine

Current guidelines recommend up to two doses of the pneumococcal conjugate heptavalent vaccine (PCV-7) in children up to 5 years old followed by and a dose of the polysaccharide vaccine (PPV-23) for patients over 2 years old to broaden serotype immunity. We assessed the serotype responses to two doses of PCV-7 and a dose of PPV-23 in a cohort of children in the 2-16-year age range in order to determine whether PPV-23 induced effective immunity to non-PCV-7 serotypes. Pneumococcal antibody concentrations to the seven serotypes covered by PCV-7 and five additional serotypes covered by PPV-23 but not PCV-7 were measured in 60 children aged 2-16 years. None of the children had a primary antibody immunodeficiency. Vaccinated children had 7-30-fold higher antibody concentrations than unvaccinated children to all serotypes contained in the PCV-7 (P<0.001). In contrast, serotypes covered by the PPV-23 but not PCV-7 were only one- to two-fold higher and there was no significant increase in the number of children who had protective concentrations of antibody ( >= 0.35 mcg/ml) against these serotypes. In this cohort of children, PPV-23 vaccine did not broaden the protection in vitro against potentially pathogenic strains of Streptococcus pneumoniae. We call into question the recommendation to use the PPV-23 in children. (c) 2007 Elsevier Ltd. All rights reserved.